• Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise

Log in

Start free trial
G2 Intelligence
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
Labs In Court: A roundup of recent cases and enforcement actions involving the diagnostics industry

Labs In Court: A roundup of recent cases and enforcement actions involving the diagnostics industry

by Glenn S. Demby | Apr 29, 2022 | Articles, Essential, Lab Compliance Advisor, Labs in Court-lca

In this month’s key cases, Myriad Genetics shells out, Illumina wins a decisive victory, a whistleblower suit is tossed, and false billing of UDTs costs a lab at least $11.6 million.

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Partnership to Create New Tool for Rapid SARS-CoV-2 Variant Detection

Partnership to Create New Tool for Rapid SARS-CoV-2 Variant Detection

by Glenn S. Demby | Mar 31, 2022 | Articles, Deals-lir, Essential, Laboratory Industry Report

Thermo Fisher, Helix, and Rosalind collaborate on an NIH-supported project to develop a new genotyping method to ID virus variants faster.

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Eight Lab Sales & Marketing Liability Pitfalls to Avoid

Eight Lab Sales & Marketing Liability Pitfalls to Avoid

by Glenn S. Demby | Feb 25, 2022 | Compliance Perspectives-lca, Essential, Lab Compliance Advisor

How to avoid eight of the most common liability pitfalls when it comes to sales and marketing operations in your lab.

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Beware of Backlash When Restructuring Commission Arrangements for EKRA Sales Commissions & EKRA Liability Risks

Beware of Backlash When Restructuring Commission Arrangements for EKRA Sales Commissions & EKRA Liability Risks

by Glenn S. Demby | Nov 21, 2021 | Articles, Compliance-lca, Essential, Lab Compliance Advisor

...

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Final Rule Clarifies Liability for Off-Label Uses and Lab’s Right to Create LDTs

Final Rule Clarifies Liability for Off-Label Uses and Lab’s Right to Create LDTs

by Glenn S. Demby | Sep 13, 2021 | Articles, Essential, FDA-lir, Laboratory Industry Report, LDTs-lir

...

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
« Older Entries
Next Entries »

Sign up for our free weekly Lab & Pathology Insider email newsletter

Log In

Join Now | Lost Password?
  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
Copyright © 2025 G2Intelligence.com